The safer effector cell? Potential of CD147 CAR NK cells to tackle tumors with lower toxicity.
作者信息
Hodges Alan, Chen Shu-Hsia, Pan Ping-Ying
机构信息
Center for Immunotherapy, Neal Cancer Center, Houston Methodist Research Institute, Houston, TX 77030, USA.
Texas A&M University System College of Medicine, Bryan, TX 77807, USA.
出版信息
Mol Ther Oncol. 2025 Jun 4;33(2):200998. doi: 10.1016/j.omton.2025.200998. eCollection 2025 Jun 18.
Abstract
摘要
相似文献
1
The safer effector cell? Potential of CD147 CAR NK cells to tackle tumors with lower toxicity.更安全的效应细胞？CD147嵌合抗原受体自然杀伤细胞以更低毒性攻克肿瘤的潜力。
Mol Ther Oncol. 2025 Jun 4;33(2):200998. doi: 10.1016/j.omton.2025.200998. eCollection 2025 Jun 18.
2
CD147-CAR-NK cell therapy shows minimal toxicities in human CD147 transgenic mouse model with solid tumors.CD147嵌合抗原受体自然杀伤细胞（CD147-CAR-NK）疗法在携带实体瘤的人CD147转基因小鼠模型中显示出极低的毒性。
Mol Ther Oncol. 2025 Feb 26;33(1):200957. doi: 10.1016/j.omton.2025.200957. eCollection 2025 Mar 20.
3
Emerging combined CAR-NK cell therapies in cancer treatment: Finding a dancing partner.癌症治疗中新兴的联合CAR-NK细胞疗法：寻找舞伴。
Mol Ther. 2025 Jan 3. doi: 10.1016/j.ymthe.2024.12.057.
4
Low Peripheral Blood Counts and Elevated Proinflammatory Cytokines Signal a Poor CD19 Chimeric Antigen Receptor T-cell Response in Acute Lymphoblastic Leukemia.外周血计数低和促炎细胞因子升高提示急性淋巴细胞白血病患者CD19嵌合抗原受体T细胞反应不佳。
Transplant Cell Ther. 2025 May 20. doi: 10.1016/j.jtct.2025.05.003.
5
CAR-NK, a Splendid Strategy for Cancer, Especially for Gynecologic Tumor.嵌合抗原受体自然杀伤细胞疗法（CAR-NK），一种治疗癌症的卓越策略，尤其适用于妇科肿瘤。
Immun Inflamm Dis. 2025 Jun;13(6):e70210. doi: 10.1002/iid3.70210.
6
Mitigation and Management of Common Toxicities Associated with the Administration of CAR-T Therapies in Oncology Patients.肿瘤患者接受CAR-T疗法相关常见毒性的缓解与管理
Drug Saf. 2025 Mar 19. doi: 10.1007/s40264-025-01538-5.
7
Geometric immunosuppression in CAR T-cell treatment: Insights from mathematical modeling.嵌合抗原受体T细胞治疗中的几何免疫抑制：来自数学建模的见解
Comput Biol Med. 2025 Aug;194:110427. doi: 10.1016/j.compbiomed.2025.110427. Epub 2025 Jun 11.
8
Latest updates on pathogenesis mechanisms and management strategies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis related to CAR-T cell therapies.嵌合抗原受体T细胞（CAR-T）疗法相关的细胞因子释放综合征、神经毒性和噬血细胞性淋巴组织细胞增生症的发病机制及管理策略的最新进展
Ann Hematol. 2025 Jun 19. doi: 10.1007/s00277-025-06467-y.
9
The high efficacy of claudin18.2-targeted CAR-T cell therapy in advanced pancreatic cancer with an antibody-dependent safety strategy.具有抗体依赖性安全策略的Claudin18.2靶向嵌合抗原受体T细胞疗法在晚期胰腺癌中的高效性
Mol Ther. 2025 Jan 10. doi: 10.1016/j.ymthe.2025.01.012.
10
Targeting Regnase-1 unleashes CAR T cell antitumor activity for osteosarcoma and creates a proinflammatory tumor microenvironment.靶向核糖核酸酶-1可释放嵌合抗原受体（CAR）T细胞对骨肉瘤的抗肿瘤活性，并营造促炎性肿瘤微环境。
bioRxiv. 2025 May 23:2025.05.20.650777. doi: 10.1101/2025.05.20.650777.
本文引用的文献
1
CD147-CAR-NK cell therapy shows minimal toxicities in human CD147 transgenic mouse model with solid tumors.CD147嵌合抗原受体自然杀伤细胞（CD147-CAR-NK）疗法在携带实体瘤的人CD147转基因小鼠模型中显示出极低的毒性。
Mol Ther Oncol. 2025 Feb 26;33(1):200957. doi: 10.1016/j.omton.2025.200957. eCollection 2025 Mar 20.
2
CAR T cells outperform CAR NK cells in CAR-mediated effector functions in head-to-head comparison.在直接比较中，嵌合抗原受体（CAR）T细胞在CAR介导的效应功能方面优于CAR自然杀伤（NK）细胞。
Exp Hematol Oncol. 2024 May 14;13(1):51. doi: 10.1186/s40164-024-00522-6.
3
Breakthrough of solid tumor treatment: CAR-NK immunotherapy.实体瘤治疗的突破：CAR-NK免疫疗法。
Cell Death Discov. 2024 Jan 20;10(1):40. doi: 10.1038/s41420-024-01815-9.
4
Forks in the road for CAR T and CAR NK cell cancer therapies.嵌合抗原受体 T（CAR T）和自然杀伤（NK）细胞癌症疗法的分岔口。
Nat Immunol. 2023 Dec;24(12):1994-2007. doi: 10.1038/s41590-023-01659-y. Epub 2023 Nov 27.
5
CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances.实体瘤治疗时代的嵌合抗原受体细胞治疗：当前的挑战和新出现的治疗进展。
Mol Cancer. 2023 Jan 30;22(1):20. doi: 10.1186/s12943-023-01723-z.
6
Development of a novel human CD147 knock-in NSG mouse model to test SARS-CoV-2 viral infection.开发一种新型人CD147基因敲入的NSG小鼠模型以测试新型冠状病毒2型（SARS-CoV-2）病毒感染。
Cell Biosci. 2022 Jun 11;12(1):88. doi: 10.1186/s13578-022-00822-6.
7
Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma.抗 CD147 嵌合抗原受体靶向治疗肝细胞癌的疗效。
Nat Commun. 2020 Sep 23;11(1):4810. doi: 10.1038/s41467-020-18444-2.
8
CAR-NK cells: A promising cellular immunotherapy for cancer.嵌合抗原受体自然杀伤细胞：癌症有前途的细胞免疫疗法。
EBioMedicine. 2020 Sep;59:102975. doi: 10.1016/j.ebiom.2020.102975. Epub 2020 Aug 24.
9
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.嵌合抗原受体修饰的自然杀伤细胞在 CD19 阳性淋巴肿瘤中的应用。
N Engl J Med. 2020 Feb 6;382(6):545-553. doi: 10.1056/NEJMoa1910607.
10
Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients.结直肠癌患者中 NKG2D CAR mRNA 修饰的自然杀伤细胞过继转移。
Mol Ther. 2019 Jun 5;27(6):1114-1125. doi: 10.1016/j.ymthe.2019.03.011. Epub 2019 Mar 20.
Zotero 插件